Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 555Lymphoma 447Precursor Cell Lymphoblastic Leukemia-Lymphoma 413Lymphoma, Large B-Cell, Diffuse 348Leukemia 346Multiple Myeloma 336Lymphoma, Non-Hodgkin 317Leukemia, Myeloid, Acute 289Leukemia, Lymphocytic, Chronic, B-Cell 286Lymphoma, Follicular 241Burkitt Lymphoma 217Myelodysplastic Syndromes 211Lymphoma, Mantle-Cell 202Hodgkin Disease 193Recurrence 153Lymphoma, B-Cell, Marginal Zone 142Melanoma 135Lymphoma, Large-Cell, Immunoblastic 116Neoplasms 109Lymphoma, B-Cell 103Neuroblastoma 101Neoplasms, Plasma Cell 99Triple Negative Breast Neoplasms 94Ovarian Neoplasms 94Leukemia, Myelogenous, Chronic, BCR-ABL Positive 91Myeloproliferative Disorders 87Hematologic Neoplasms 87Leukemia, Myeloid, Chronic-Phase 83Leukemia, Myeloid, Accelerated Phase 80Leukemia, Myelomonocytic, Chronic 78

Interventions

Doxorubicin 6Ifosfamide 5Radiotherapy 4pazopanib 3cediranib 3atezolizumab 3Sunitinib 3selinexor 2perifosine 2pembrolizumab 2Trabectedin 2Specimen Handling 2Loperamide 2Gemcitabine 2Filgrastim 2Dacarbazine 2Cisplatin 2Biopsy 2Bevacizumab 2trifluridine tipiracil drug combination 1spartalizumab 1sargramostim 1romidepsin 1lentiviral minigene vaccine of COVID-19 coronavirus 1ixazomib 1indolepropanol phosphate 1futibatinib 1fludarabine 1cabozantinib 1brostallicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Alveolar Soft Part × Cyclophosphamide × Clear all
NCT07297667 2026-05-12

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Canadian Cancer Trials Group

Phase 1 Not yet recruiting
30 enrolled
BreastGenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡